Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors

BACKGROUND: Given the observed antitumor activity of immune-checkpoint-inhibitors in patients with mismatch-repair deficient (MSI-H) tumors, we hypothesized that deficiency in homologous-recombination-repair (HRR) can also influence susceptibility. METHODS: Patients with disease progression on stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Villalona-Calero, Miguel A., Diaz, John P., Duan, Wenrui, Diaz, Zuanel, Schroeder, Eric D., Aparo, Santiago, Gatcliffe, Troy, Albrecht, Federico, Venkatappa, Siddhartha, Guardiola, Victor, Garrido, Sara, Rubens, Muni, DeZarraga, Fernando, Vuong, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164357/
https://www.ncbi.nlm.nih.gov/pubmed/35658948
http://dx.doi.org/10.1186/s40364-022-00386-0

Ejemplares similares

Ejemplares similares